Bliss GVS Pharma elevates CEO S.N. Kamath to Managing Director for 3 years

Management Changes View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹177.61

prior close

₹179.30

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-0.9% vs market

Pharmaceuticals peers, median of 154sector-0.5%-1.0% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-1.0

15m

-1.2

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5-0.5-0.9-0.5-1.0

Next day

-6.3-1.1-5.2-0.9-5.3

-8.1-1.8-6.3-1.7-6.5

-8.8-1.9-6.9-1.7-7.1

-7.9-0.5-7.4-1.0-6.9

-8.8-0.3-8.5-1.0-7.8

-9.9+0.9-10.7-0.7-9.1

15d

-3.3-4.3+1.0-3.9+0.5

-6.1-9.3+3.2-8.3+2.2

+20.4-5.4+25.8-7.6+28.0

+16.3-13.7+30.0-13.6+29.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bliss GVS Pharma Board has appointed Mr. S.N. Kamath as Managing Director for 3 years, effective from the date of shareholder approval via Postal Ballot. Kamath currently serves as CEO and is a promoter of the company. He is the father of two existing Whole-Time Directors, Dr. Vibha Gagan Sharma and Mrs. Shruti Vishal Rao. Upon shareholder approval, he will hold the combined title of Managing Director and CEO. The appointment is subject to passing of a Special Resolution by shareholders through Postal Ballot.

Likely market impact

Likely neutral; formal elevation of an existing insider keeps leadership continuity. Awaiting shareholder approval via Postal Ballot.